An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia
Objective: Trastuzumab (Herceptin®), a recombinant, humanized, monoclonal antibody targeting HER2 is well established as an effective treatment for HER2-positive breast cancer. Evidence from developed countries showed that trastuzumab was cost-effective; but there are few evidences in developing cou...
Gardado en:
| Publicado en: | Biomédica |
|---|---|
| Principais autores: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Instituto Nacional de Salud
2013
|
| Assuntos: | |
| Acceso en liña: | https://www.redalyc.org/articulo.oa?id=84329151010 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|